Last reviewed · How we verify
AZD1656
At a glance
| Generic name | AZD1656 |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce (PHASE2)
- AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 (PHASE2)
- Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes (PHASE2)
- Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients (PHASE2)
- Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin (PHASE2)
- Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients (PHASE2)
- A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients (PHASE1)
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD1656 CI brief — competitive landscape report
- AZD1656 updates RSS · CI watch RSS
- AstraZeneca portfolio CI